Comvita (CVT) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
14 May, 2026Refinancing and capital raise details
Refinancing package agreed with lenders, conditional on a minimum $25m capital raise, with proceeds used to reduce existing bank facilities.
$30m pro rata renounceable rights offer at $0.65 per share, with F&N as a strategic investor, potentially acquiring up to 19.99% post-raise.
Strategic Placement shares to F&N priced at $0.80, a premium to the rights offer price and TERP.
Two new facilities: $20m working capital (repaid annually) and up to $30m core debt, with leverage and ICR covenants tested quarterly.
Capital raise size scenarios range from $25m to $44m, with F&N partially underwriting the offer and final shareholding dependent on take-up.
Strategic partnership with F&N
F&N, a leading Southeast Asian consumer group, brings deep market knowledge and distribution in ASEAN.
Collaboration aims to accelerate market expansion, innovation, and operational efficiencies.
F&N to appoint a director to the board post-raise.
F&N operates in 12 countries, with SG$2.3bn revenue and strong presence in Malaysia, Thailand, and Singapore.
Financial guidance and balance sheet impact
FY26 normalised EBIT guidance of $15.5m reaffirmed, with focus on volume, cost control, and key value drivers.
Inventory normalisation ahead of plan, with net debt reduced by $14m from FY25 to 1H26.
Capital raise proceeds to significantly deleverage the balance sheet, reducing leverage to as low as 0.7x in high take-up scenarios.
Continued focus on cash conversion, inventory management, and debt reduction.
Latest events from Comvita
- FY24 saw steep financial declines; FY25 will focus on cost control, innovation, and reset.CVT
AGM 202414 May 2026 - Net profit $4.6m, revenue $118m, strong cash flow; North America drives growth, recapitalisation ongoing.CVT
H1 202623 Feb 2026 - Revenue and profit fell sharply amid impairments and market contraction, with cost cuts in progress.CVT
H2 202423 Jan 2026 - Net loss of $6.5M, revenue down, but cash flow and inventory improved amid restructuring.CVT
H1 202524 Dec 2025 - Financial reset, recapitalisation, and board changes drive growth amid market challenges.CVT
AGM 202517 Dec 2025 - Revenue down 4.1%, major loss from impairments, but cash flow and debt improved; 67% premium offer.CVT
H2 202523 Nov 2025